Brief: Harrow Announces Availability Of Vevye
11/01/2024 12:12
Jan 11 (Reuters) - Harrow Inc HROW.O :
* HARROW ANNOUNCES AVAILABILITY OF VEVYE® (CYCLOSPORINE
OPHTHALMIC
SOLUTION) 0.1%, THE FIRST AND ONLY CYCLOSPORINE-BASED PRODUCT
INDICATED FOR TREATING BOTH SIGNS AND SYMPTOMS OF DRY EYE
DISEASE
Source text for Eikon: ID:nBw26LR2ga
Further company coverage: HROW.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates